Skip to main content
. 2016 Jul 18;6:29969. doi: 10.1038/srep29969

Figure 3. DHMD targets the early phase of HCV infection.

Figure 3

(a) Schematics of the treatment analyses in the time-of-drug-addition assay. (b) Pretreatment effect of DHMD on Huh-7.5 cells before HCVcc infection (MOI = 0.01). (c) Coaddition treatment effect of DHMD and HCVcc inoculum on Huh-7.5 cells (MOI = 0.01). (d) Postinfection treatment effect of DHMD of Huh-7.5 cells infected with HCVcc (MOI = 0.01). Results were obtained using luciferase analysis following 72 h of incubation. DHMD = 50 μM; DMSO = 0.5%; IFN-α = 1,000 IU/ml. Data shown are means ± SEM (*P < 0.05) from 3 independent experiments.